Trial record 1 of 1 for:
CLN-617
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06035744 |
|
Recruitment Status :
Recruiting
First Posted : September 13, 2023
Last Update Posted : May 2, 2024
|
Sponsor:
Cullinan Therapeutics Inc.
Information provided by (Responsible Party):
Cullinan Therapeutics Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2028 |
| Estimated Study Completion Date : | June 2028 |